Yonsung Fine Chemical Co., Ltd.

Dongkook Pharmaceutical Co., Ltd.

Ys Life Science Co. Ltd.

Kee Young Lee

Chang Young Oh

Yong Hyun Kim

Hyun Ik Shin

Changyoung Oh

Won Hun Ham

Jin Kyu Park

Han Won Lee

Sung Ki Seo

Areum Baek

Hyoseon Lee

Kyung Seok Choi

Min Sung Park

Young Hun Jung

Youngsik Chung

Yiu Suk Lee

Kyung Jin Lee

Eun Jeong Ko

Jae Eun Joo

An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol.

Ophthalmic composition for glaucoma treatment

The present invention relates to a process for preparing latanoprostene bunod and an intermediate therefor. In accordance with the preparation process of the present invention, latanoprostene bunod can be efficiently and cost-effectively prepared while reducing side reactions.

Method for preparing latanoprostene bunod, and intermediate therefor

The present invention relates to a cost-effective and efficient method for preparing treprostinil with high purity, and an intermediate therefor.

Method for preparing treprostinil and intermediate therefor

A method for preparing a 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivative by a simple process with high yields, and an intermediate useful for the method.

Method for preparing 3-((2S, 5S)-4-methylene-5-(3-oxopropyl)tetrahydrofurane-2-yl) propanol derivative, and intermediate therefor

The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

Process for preparing prostaglandin derivatives

The present invention relates to a novel process for preparing sulfamoyl-substituted phenethylamine derivatives, specifically, 5-{2-[2-(2-alkoxy-phenoxy)ethylamino]-propyl}-2-methoxy-benzene sulfonamide of the formula (1).

Process for preparing sulfamoyl-substituted phenethylamine derivatives

The present invention relates to a process for the preparation of an oxazoline compound which is easily chemically converted to a beta-amino-alpha-hydroxy acid or a gamma-amino-beta-hydroxy acid. The method comprises producing a compound of the following formula (4) using .alpha.-amino acid. The produced compound (4) is subjected to an intramolecular cyclization to produce an oxazoline compound of the following formula (3). The oxazoline compound (3) is oxidized at a vinyl group with RuCl.sub.3 or NaIO.sub.4 to produce an oxazoline compound of the following formula (1) which is easily chemically converted to a beta-amino-alpha-hydroxy acid. Alternatively, the oxazoline compound (3) may also be treated with 9-borabiclo[3.3.1]nonane such that a hydroxy group is introduced into the end of the vinyl group of the oxazoline compound(3). The introduced end hydroxy group is oxidized with RuCl.sub.3 or NaIO.sub.4 to produce an oxazoline compound of the following formula (2) which is easily chemically converted to a gamma-amino-hydroxy acid.

Process for the preparation of oxazoline compound

A preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid includes the steps of: mixing N-alkoxycarbonyl-.beta.-alanine, phosphorous chloride and phosphorous acid in the ratio of 1:1:1.about.1:3:3 in a reaction solvent, xylene at 70.degree.-140.degree. C.; hydrolyzing; and obtaining 3-amino-1-hydroxypropane-1,1-diphosphonic acid as a product, thus decreasing the production of unidentified by-products and giving and low production cost by using xylene instead of chlorobenzene as a reaction solvent.

Growing community of inventors

Seoul, South Korea

Kee Young Lee